Composition for long-acting peptide analogs
First Claim
1. A composition comprising a peptide analog having a general formula:
- A-(Cm)x-(peptide), wherein;
a. Cm is each independently lysine or arginine;
b. x is an integer from 3-6;
c. A is an alkyl group with 6 to 36 carbon units with a linker group selected from carbonyl and amino; and
d. the peptide is selected from vasopressin or a derivative thereof, terlipressin or a derivative thereof, glucagon like peptide (GLP), leptin fragment, gastric inhibitory polypeptide (GIP), epidermal growth factor (EGF) receptor ligand, EGF, transforming growth factor alpha (TGF-alpha), gastrin/cholecystokinin receptor ligand, gastrin, cholecystokinin, auristatin, nisin, insulin, insulin-like growth factor, parathyroid hormone (PTH), atrial natriuretic factor, somatostatin, gonadotropin releasing hormone, leutinizing-hormone-releasing-hormone, and vasoactive intestinal peptide (VIP).
2 Assignments
0 Petitions
Accused Products
Abstract
The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.
146 Citations
37 Claims
-
1. A composition comprising a peptide analog having a general formula:
- A-(Cm)x-(peptide), wherein;
a. Cm is each independently lysine or arginine; b. x is an integer from 3-6; c. A is an alkyl group with 6 to 36 carbon units with a linker group selected from carbonyl and amino; and d. the peptide is selected from vasopressin or a derivative thereof, terlipressin or a derivative thereof, glucagon like peptide (GLP), leptin fragment, gastric inhibitory polypeptide (GIP), epidermal growth factor (EGF) receptor ligand, EGF, transforming growth factor alpha (TGF-alpha), gastrin/cholecystokinin receptor ligand, gastrin, cholecystokinin, auristatin, nisin, insulin, insulin-like growth factor, parathyroid hormone (PTH), atrial natriuretic factor, somatostatin, gonadotropin releasing hormone, leutinizing-hormone-releasing-hormone, and vasoactive intestinal peptide (VIP). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
- A-(Cm)x-(peptide), wherein;
-
19. A composition comprising a peptide analog having a general formula:
- A-(Cm)x-(peptide), wherein;
a. Cm is each independently lysine, glycine, or arginine; b. x is an integer from 2-6; c. A is an alkyl group with 6 to 36 carbon units with a linker group selected from carbonyl and amino; and d. the peptide comprises atrial natriuretic factor. - View Dependent Claims (20, 21, 22, 23)
- A-(Cm)x-(peptide), wherein;
Specification